share_log

Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform, Lowers Price Target to $1

Benzinga ·  May 16 01:28

Leerink Partners analyst Daina Graybosch downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Outperform to Market Perform and lowers the price target from $3 to $1.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment